Pharmafile Logo
Pharmafocus logo
Advanced Search

biosimilar

Showing 15 posts of 73 posts found.

Alvotech and Advanz Pharma announce commercialisation agreement for Eylea biosimilar

June 18, 2024
Sales and Marketing Advanz Pharma, Alvotech, Opthalmology, biosimilar

Alvotech and Advanz Pharma have announced an exclusive partnership agreement surrounding the supply and commercialisation of AVT06, Alvotech’s proposed biosimilar …

News

Boan Biotech completes enrolment for phase 3 study of Denosumab

January 15, 2024
Research and Development Boan Biotech, Pharmacy, biosimilar, clinical trial, denosumab

Boan Biotech has announced that it has completed subject enrolment for its international multicentre comparative phase 3 clinical trial of …

News

Alvotech and JAMP Pharma’s Jamteki gains marketing authorisation from Health Canada

November 15, 2023
Medical Communications Alvotech, Health Canada, JAMP Pharma, Pharmacy, biosimilar

Alvotech and JAMP Pharma have announced that Health Canada has granted JAMP Pharma marketing authorisation for AVT04, a biosimilar to …

News

NICE release new guidance on rheumatoid arthritis treatment

June 10, 2021
NICE, biosimilar, rheumatoid arthritis

NICE has today published final draft guidance for the treatment of moderate rheumatoid arthritis in patients who have not responded …

News
celltrion1

Celltrion’s Humira biosimilar is comparable in treating rheumatoid arthritis

November 4, 2020
Research and Development Humira, biosimilar, celltrion, rheumatoid arthritis

Celltrion has revealed new Phase 3 data demonstrating that its high concentration (100mg/mL) and citrate-free biosimilar CT-P17 proved comparable to …

News
shutterstock_36423250

China approves its first biosimilar of Roche’s Herceptin in HER2+ cancers

August 18, 2020
Manufacturing and Production, Sales and Marketing China, Henlius, Herceptin, Roche, biosimilar

China’s National Medical Products Administration (NMPA) has given the green light to Shanghai’s Henlius for its biosimilar version of Roche’s …

News

Pfizer scores EU approval for MabThera biosimilar Ruxience

April 6, 2020
Sales and Marketing MabThera, Pfizer, Ruxience, biosimilar

The European Commission has moved to authorise Ruxience, Pfizer’s biosimilar version of MabThera (rituximab).  The decision marks the seventh biosimilar …

News

Europe’s CHMP recommends Pfizer’s biosimilar of Roche’s MabThera

February 4, 2020
Manufacturing and Production, Sales and Marketing MabThera, Pfizer, Ruxience, biosimilar, pharma

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has revealed that it has awarded a positive opinion for …

News

Pfizer’s Humira biosimilar secures FDA approval, due to launch in 2023

November 18, 2019
Sales and Marketing Abrilada, FDA, Humira, Pfizer, biosimilar, pharma

Pfizer has confirmed the FDA approval of Abrilada (adalimumab-afzb),  its biosimilar version of AbbVie’s Humira, the world’s best-selling drug,   …

News
celltrion1

Celltrion’s subcutaneous infliximab biosimilar secures CHMP recommendation

September 24, 2019
Manufacturing and Production, Sales and Marketing EMA, EU, Europe, biosimilar, celltrion, infliximab, pharma

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has given its recommendation to Celltrion’s CT-P13 SC, the subcutaneous …

News
sandoz

Sandoz acquires global commercialisation rights to Polpharma’s multiple sclerosis biosimilar

September 3, 2019
Manufacturing and Production, Sales and Marketing Polpharma, Sandoz, biosimilar, multiple sclerosis, pharma

Sandoz has revealed that it has sealed a deal with Polpharma Biologics to commercialise the latter’s proposed biosimilar version of …

News

FDA approves Pfizer’s Herceptin biosimilar Trazimera

March 12, 2019
Manufacturing and Production, Sales and Marketing Humira, Pfizer, Trazimera, biosimilar, pharma

Patients in the US will now be able to access another biosimilar version of Herceptin (trastuzumab) with the FDA approval …

News
samsung

FDA approves third Herceptin biosimilar with Samsung Bioepis’ Ontruzant

January 22, 2019
Manufacturing and Production, Sales and Marketing FDA, Herceptin, Samsung Bioepis, biosimilar, pharma

Samsung Bioepis’ has announced that the FDA has chosen to approve Ontruzant (trastuzumab-dttb), its biosimilar version of Roche’s Herceptin (trastuzumab), …

News
amgen_flag

Amgen launches first biosimilar of best-selling Humira in Europe

October 16, 2018
Manufacturing and Production, Sales and Marketing Amgen, Amgevita, Humira, biosimilar, pharma

Amgen has announced the launch of a proprietary biosimilar version of Abbvie’s best-selling drug Humira (adalimumab) across all European markets, …

News
merckwindow_web

MSD and Samsung Bioepis terminate development of Lantus biosimilar for diabetes

October 15, 2018
Research and Development, Sales and Marketing Lantus, MSD, Samsung Bioepis, Sanofi, biosimilar, diabetes, pharma

MSD has reportedly terminated a previous agreement with Samsung Bioepis which would have seen them collaborate on a biosimilar version …

News

Latest content

Gilead shares phase 3 results from HIV prevention trial

June 21, 2024

Sarepta Therapeutics gains expanded FDA approval for DMD treatment

June 21, 2024

FDA approves AbbVie’s Skyrizi for UC treatment

June 20, 2024

Takeda shares data from phase 3 trial of CIPD treatment

June 20, 2024

EC grants marketing authorisation to Sobi’s Altuvoct for haemophilia A treatment

June 19, 2024